Weitz and Luxenberg Adds Serious Urinary Tract Infections to SGLT2 Inhibitor Injuries Probe
NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.